Nevertheless, studies about targeting EGFR and STAT3 in glioblastoma [147], non-small-cell lung cancer [148,149,150], and pancreatic cancer [151] exhibit promising therapeutic efficacy (Table 1). Here, STAT3 is linked to non-small cell lung carcinoma.